Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

July 31, 2015

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).

Trial Locations (1)

04023-062

Dept of Ophthalmology - UNIFESP/Hospital São Paulo, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Federal University of São Paulo

OTHER

NCT02055911 - Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter